The mission of the HESI Antibody-Drug Conjugate Safety Committee is to identify, optimize, and advance nonclinical approaches to safety evaluation of Antibody-Drug Conjugates.
This program launched in January 2024 and is developing its work program. This page will be updated as information is available or you may contact the program manager for more details.
Bristol Myers Squibb
Pending
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.